Genetic Total Current Liabilities vs Inventory Analysis

GENE Stock

USD 2.28 0.01 0.44%

Genetic Technologies financial indicator trend analysis is much more than just examining Genetic Technologies latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Genetic Technologies is a good investment. Please check the relationship between Genetic Technologies Total Current Liabilities and its Inventory accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.

Total Current Liabilities vs Inventory

Total Current Liabilities vs Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Genetic Technologies Total Current Liabilities account and Inventory. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Genetic Technologies' Total Current Liabilities and Inventory is -0.17. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Inventory in the same time period over historical financial statements of Genetic Technologies, assuming nothing else is changed. The correlation between historical values of Genetic Technologies' Total Current Liabilities and Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Genetic Technologies are associated (or correlated) with its Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory has no effect on the direction of Total Current Liabilities i.e., Genetic Technologies' Total Current Liabilities and Inventory go up and down completely randomly.

Correlation Coefficient

-0.17

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Genetic Technologies balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Genetic Technologies are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Inventory

Most indicators from Genetic Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Genetic Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 9.1 M, whereas Selling General Administrative is forecasted to decline to about 4.3 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	578.7K	676.6K	778.1K	472.1K
Interest Income	36.3K	220.2K	253.2K	265.8K

Reconciled Depreciation Interest Income

Genetic Technologies fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Long Term Debt
Total Assets		0.01	0.23	0.98	0.73	-0.86	-0.33	0.88	0.2	-0.28	0.88	0.38	0.39	0.43	-0.15	0.55	0.07	0.49	0.92	0.39	-0.28	-0.52	0.48	-0.19	-0.06	-0.26
Other Current Liab	0.01		0.71	-0.11	0.26	0.3	0.06	-0.29	0.47	-0.31	-0.29	0.33	-0.02	0.17	0.23	-0.17	0.58	0.5	-0.2	-0.01	0.58	-0.15	0.21	0.19	0.52	0.18
Total Current Liabilities	0.23	0.71		0.07	0.54	0.15	-0.39	-0.09	0.66	-0.78	-0.09	0.75	0.41	0.56	-0.17	-0.21	0.82	0.87	-0.01	0.44	0.39	-0.18	0.53	-0.25	0.67	0.12
Total Stockholder Equity	0.98	-0.11	0.07		0.64	-0.91	-0.27	0.91	0.1	-0.17	0.91	0.26	0.34	0.35	-0.11	0.59	-0.13	0.36	0.94	0.33	-0.41	-0.53	0.4	-0.14	-0.18	-0.33
Property Plant And Equipment Net	0.73	0.26	0.54	0.64		-0.38	-0.32	0.46	0.65	-0.56	0.46	0.68	0.22	0.62	-0.1	0.2	0.39	0.72	0.52	0.24	0.01	-0.35	0.62	-0.18	0.4	-0.04
Net Debt	-0.86	0.3	0.15	-0.91	-0.38		0.4	-0.99	0.28	0.07	-0.99	-0.09	-0.48	-0.2	0.33	-0.65	0.25	-0.13	-0.96	-0.46	0.47	0.53	-0.21	0.32	0.51	0.46
Retained Earnings	-0.33	0.06	-0.39	-0.27	-0.32	0.4		-0.46	0.14	0.75	-0.46	-0.66	-0.91	-0.69	0.73	-0.26	-0.3	-0.51	-0.43	-0.91	0.14	0.5	-0.51	0.76	0.2	0.54
Cash	0.88	-0.29	-0.09	0.91	0.46	-0.99	-0.46		-0.23	-0.15	1.0	0.22	0.52	0.31	-0.36	0.65	-0.15	0.2	0.98	0.5	-0.42	-0.57	0.3	-0.36	-0.45	-0.46
Non Current Assets Total	0.2	0.47	0.66	0.1	0.65	0.28	0.14	-0.23		-0.4	-0.23	0.46	-0.22	0.35	0.18	-0.27	0.45	0.57	-0.15	-0.18	0.33	0.12	0.38	0.1	0.78	0.46
Non Currrent Assets Other	-0.28	-0.31	-0.78	-0.17	-0.56	0.07	0.75	-0.15	-0.4		-0.15	-0.85	-0.65	-0.74	0.43	0.12	-0.57	-0.81	-0.19	-0.68	0.0	0.46	-0.63	0.51	-0.41	0.32
Cash And Short Term Investments	0.88	-0.29	-0.09	0.91	0.46	-0.99	-0.46	1.0	-0.23	-0.15		0.22	0.52	0.31	-0.36	0.65	-0.15	0.2	0.98	0.5	-0.41	-0.56	0.3	-0.37	-0.46	-0.45
Net Receivables	0.38	0.33	0.75	0.26	0.68	-0.09	-0.66	0.22	0.46	-0.85	0.22		0.55	0.91	-0.24	0.03	0.63	0.84	0.3	0.59	0.06	-0.46	0.8	-0.33	0.48	-0.29
Common Stock Total Equity	0.39	-0.02	0.41	0.34	0.22	-0.48	-0.91	0.52	-0.22	-0.65	0.52	0.55		0.58	-0.69	0.31	0.28	0.54	0.51	1.0	-0.17	-0.48	0.43	-0.69	-0.27	-0.5
Common Stock Shares Outstanding	0.43	0.17	0.56	0.35	0.62	-0.2	-0.69	0.31	0.35	-0.74	0.31	0.91	0.58		-0.16	0.27	0.37	0.77	0.4	0.62	-0.1	-0.59	0.91	-0.23	0.26	-0.44
Inventory	-0.15	0.23	-0.17	-0.11	-0.1	0.33	0.73	-0.36	0.18	0.43	-0.36	-0.24	-0.69	-0.16		-0.14	-0.21	-0.09	-0.23	-0.67	-0.12	-0.01	0.08	0.99	0.37	0.02
Other Stockholder Equity	0.55	-0.17	-0.21	0.59	0.2	-0.65	-0.26	0.65	-0.27	0.12	0.65	0.03	0.31	0.27	-0.14		-0.23	-0.02	0.64	0.29	-0.14	-0.34	0.16	-0.11	-0.46	-0.2
Total Liab	0.07	0.58	0.82	-0.13	0.39	0.25	-0.3	-0.15	0.45	-0.57	-0.15	0.63	0.28	0.37	-0.21	-0.23		0.62	-0.09	0.31	0.64	0.06	0.41	-0.25	0.6	0.32
Property Plant And Equipment Gross	0.49	0.5	0.87	0.36	0.72	-0.13	-0.51	0.2	0.57	-0.81	0.2	0.84	0.54	0.77	-0.09	-0.02	0.62		0.31	0.58	0.01	-0.46	0.77	-0.18	0.52	-0.22
Total Current Assets	0.92	-0.2	-0.01	0.94	0.52	-0.96	-0.43	0.98	-0.15	-0.19	0.98	0.3	0.51	0.4	-0.23	0.64	-0.09	0.31		0.49	-0.43	-0.63	0.42	-0.25	-0.34	-0.49
Common Stock	0.39	-0.01	0.44	0.33	0.24	-0.46	-0.91	0.5	-0.18	-0.68	0.5	0.59	1.0	0.62	-0.67	0.29	0.31	0.58	0.49		-0.17	-0.49	0.47	-0.68	-0.23	-0.5
Short Long Term Debt Total	-0.28	0.58	0.39	-0.41	0.01	0.47	0.14	-0.42	0.33	0.0	-0.41	0.06	-0.17	-0.1	-0.12	-0.14	0.64	0.01	-0.43	-0.17		0.44	-0.1	-0.11	0.26	0.71
Other Current Assets	-0.52	-0.15	-0.18	-0.53	-0.35	0.53	0.5	-0.57	0.12	0.46	-0.56	-0.46	-0.48	-0.59	-0.01	-0.34	0.06	-0.46	-0.63	-0.49	0.44		-0.58	0.04	0.11	0.77
Short Term Debt	0.48	0.21	0.53	0.4	0.62	-0.21	-0.51	0.3	0.38	-0.63	0.3	0.8	0.43	0.91	0.08	0.16	0.41	0.77	0.42	0.47	-0.1	-0.58		0.01	0.31	-0.42
Intangible Assets	-0.19	0.19	-0.25	-0.14	-0.18	0.32	0.76	-0.36	0.1	0.51	-0.37	-0.33	-0.69	-0.23	0.99	-0.11	-0.25	-0.18	-0.25	-0.68	-0.11	0.04	0.01		0.29	0.04
Accounts Payable	-0.06	0.52	0.67	-0.18	0.4	0.51	0.2	-0.45	0.78	-0.41	-0.46	0.48	-0.27	0.26	0.37	-0.46	0.6	0.52	-0.34	-0.23	0.26	0.11	0.31	0.29		0.33
Long Term Debt	-0.26	0.18	0.12	-0.33	-0.04	0.46	0.54	-0.46	0.46	0.32	-0.45	-0.29	-0.5	-0.44	0.02	-0.2	0.32	-0.22	-0.49	-0.5	0.71	0.77	-0.42	0.04	0.33

Click cells to compare fundamentals

Genetic Technologies Account Relationship Matchups

Genetic Technologies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.6M	23.0M	20.8M	14.9M	13.4M	14.4M
Other Current Liab	806.5K	955.5K	1.6M	1.3M	1.2M	989.0K
Total Current Liabilities	1.4M	1.4M	3.8M	3.3M	3.0M	2.0M
Total Stockholder Equity	13.0M	21.5M	16.4M	11.2M	10.0M	12.0M
Property Plant And Equipment Net	440.2K	637.7K	953.3K	599.2K	539.3K	863.9K
Net Debt	(13.7M)	(20.7M)	(11.1M)	(7.3M)	(6.6M)	(6.9M)
Retained Earnings	(135.9M)	(143.1M)	(150.2M)	(156.7M)	(141.0M)	(134.0M)
Cash	14.2M	20.9M	11.7M	7.9M	9.0M	9.8M
Non Current Assets Total	440.2K	735.6K	6.1M	4.4M	3.9M	5.9M
Non Currrent Assets Other	(440.2K)	97.9K	(6.1M)	(4.2M)	(3.8M)	(3.6M)
Cash And Short Term Investments	14.2M	20.9M	11.7M	7.9M	9.0M	9.9M
Net Receivables	789.4K	1.1M	2.4M	1.9M	2.2M	2.3M
Common Stock Total Equity	122.4M	125.5M	140.1M	153.6M	176.6M	89.1M
Common Stock Shares Outstanding	41.6M	85.4M	92.2M	101.4M	116.6M	122.4M
Liabilities And Stockholders Equity	15.6M	23.0M	20.8M	14.9M	13.4M	14.4M
Inventory	91.4K	76.9K	398.2K	325.9K	293.3K	479.5K
Other Stockholder Equity	13.0M	162.0M	11.5M	6.5M	7.5M	7.1M
Total Liab	2.6M	1.4M	4.4M	3.7M	3.3M	2.3M
Property Plant And Equipment Gross	440.2K	637.7K	1.9M	1.8M	1.6M	913.1K
Total Current Assets	15.2M	22.2M	14.7M	10.5M	12.1M	11.7M
Common Stock	140.1M	153.6M	155.1M	161.3M	185.5M	95.3M
Short Long Term Debt Total	481.8K	204.0K	652.5K	532.8K	479.6K	402.1K
Other Current Assets	97.8K	1.9K	18.2K	17.4K	15.7K	14.9K
Short Term Debt	240.9K	179.6K	264.1K	303.6K	273.2K	286.9K
Accounts Payable	350.2K	269.7K	1.2M	838.0K	754.2K	882.3K
Short Term Investments	2.0K	1.9K	13.3K	17.4K	15.7K	14.9K
Property Plant Equipment	440.2K	637.7K	953.3K	599.2K	539.3K	759.3K
Non Current Liabilities Total	1.2M	33.3K	558.9K	381.6K	343.5K	400.6K
Accumulated Other Comprehensive Income	8.8M	11.0M	11.5M	6.5M	7.5M	4.4M
Other Liab	979.2K	8.9K	170.5K	152.3K	175.2K	128.6K
Net Tangible Assets	13.0M	21.5M	11.3M	7.5M	8.7M	10.6M
Capital Lease Obligations	429.5K	204.0K	652.5K	532.8K	612.8K	643.4K
Net Invested Capital	13.1M	21.5M	16.4M	11.2M	12.8M	12.5M
Net Working Capital	13.8M	20.8M	10.9M	7.2M	8.3M	10.9M
Capital Stock	140.1M	153.6M	155.1M	161.3M	185.5M	161.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GOOG	Alphabet Inc Class C
C	Citigroup
GOOG	Alphabet Inc Class C

When determining whether Genetic Technologies is a strong investment it is important to analyze Genetic Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Genetic Technologies' future performance. For an informed investment choice regarding Genetic Stock, refer to the following important reports:

How To Invest In Genetic

Details

Is Genetic Stock a good investment?

Details

What is Genetic Technologies' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Genetic Stock analysis

When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.

	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Stocks Directory Find actively traded stocks across global markets
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume

Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.15)

Revenue Per Share

2.73

Quarterly Revenue Growth

(0.02)

Return On Assets

(0.53)

Return On Equity

(1.60)

The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Genetic Total Current Liabilities vs Inventory Analysis

Total Current Liabilities vs Inventory

Total Current Liabilities vs Inventory Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Inventory

Genetic Technologies fundamental ratios Correlations

Genetic Technologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Genetic Technologies fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Genetic Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Intangible Assets	+ 0.99	Inventory
Total Stockholder Equity	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Cash
Total Current Assets	+ 0.98	Cash And Short Term Investments

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.96	Net Debt
Common Stock	- 0.91	Retained Earnings
Common Stock Total Equity	- 0.91	Retained Earnings
Net Debt	- 0.91	Total Stockholder Equity